Investing.com -- KKR & Co (NYSE: KKR )., a New York-based investment firm, is nearing the completion of a deal to acquire Karo Healthcare, a Swedish consumer-health business. The deal could value Karo at over €2.5 billion ($2.7 billion), according to a report from Bloomberg, citing sources familiar with the matter.

The acquisition process is in its final stages, with KKR finalizing the terms of the transaction with Karo’s current owner, EQT AB (ST: EQTAB ). KKR managed to outbid other private equity firms in the bidding process, the sources noted. An official announcement of the deal could be made as early as this week, the sources added, requesting anonymity due to the private nature of the information.

Karo Healthcare, headquartered in Stockholm, employs approximately 460 people and sells its products in over 90 countries, according to the company’s website. Karo’s portfolio includes the E45 dermatology brand, as well as products for coughs, colds, and vitamins.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.